

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

Neither this announcement nor any copy thereof may be released into or distributed directly or indirectly in the United States or any other jurisdiction where such release or distribution might be unlawful. This announcement is for information purpose only and does not constitute an invitation or offer to acquire, purchase or subscribe for any securities of Shanghai MicroPort MedBot (Group) Co., Ltd. (the “Company”).

This announcement is not for release, publication, distribution, directly or indirectly, in or into the United States (including its territories and possessions, any state of the United States and the District of Columbia).

This announcement does not constitute or form a part of any offer to sell or solicitation to purchase or subscribe for securities in the United States or in any other jurisdictions where such offer is unlawful. The securities mentioned in this announcement have not been, and will not be, registered under the United States Securities Act of 1933, as amended from time to time (the “U.S. Securities Act”) or any state securities laws of the United States and may not be offered or sold in the United States absent registration or an applicable exemption from registration. Any public offering of securities to be made in the United States will be made by means of a prospectus. Such prospectus will contain detailed information about the Company making the offer and its management, as well as its financial statements. No public offer of securities is to be made by the Company in the United States.



Shanghai MicroPort MedBot (Group) Co., Ltd.

上海微创医疗机器人(集团)股份有限公司

(a joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 2252)

COMPLETION OF PLACING OF NEW H SHARES UNDER GENERAL MANDATE

Overall Coordinators and Joint Placing Agents

J.P.Morgan



Reference is made to the announcement of the Company dated 27 June 2024 (the “**Announcement**”) in relation to, among other things, the Placing. Capitalised terms used but not otherwise defined herein shall have the same meanings as those defined in the Announcement.

COMPLETION OF THE PLACING

The Company is pleased to announce that completion of the Placing took place on 5 July 2024.

A total of 12,900,000 Placing Shares have been successfully placed at the Placing Price of HK\$9.10 per H Share to no less than six placees, who, together with their respective ultimate beneficial owners, are third parties independent of, and not connected with, the Company and the connected persons of the Company. None of the placees has become a substantial shareholder (as defined in the Listing Rules) of the Company immediately after the completion of the Placing.

PROCEEDS FROM THE PLACING

The Company received total net proceeds from the Placing (after deducting all relevant fees, costs and expenses to be borne or incurred by the Company) of approximately HK\$114.08 million. The net Placing Price, after deducting such fees, costs and expenses, is therefore approximately HK\$8.84 per Placing Share.

The Company intends to apply the net proceeds from the Placing in the following manners: (i) 40% for development of the Group's core business and formulation for the Group's business ecosystem, including but not limited to overseas product registration and corresponding improvement works, overseas and local commercialisation of the Group's products, academic promotion, medical trainings and after-sale services; (ii) 30% for continuous improvement, optimization and upgrade on products; and (iii) 30% for replenishing working capital and general corporate purpose.

EFFECT ON SHAREHOLDING STRUCTURE OF THE COMPANY

The table below sets out the shareholding structure of the Company before and after the Placing:

	Immediately before completion of the Placing		As at the date of this announcement	
	<i>Class and number of Shares</i>	<i>Approx. %</i>	<i>Class and number of Shares</i>	<i>Approx. %</i>
Substantial shareholders				
Shanghai Latent Artificial Intelligence Co., Ltd. ⁽¹⁾	483,767,176 H Shares	50.47%	483,767,176 H Shares	49.80%
Shanghai Qingmin Enterprise Management Consultation Center (Limited Partnership) ⁽²⁾	96,013,252 H Shares	10.02%	96,013,252 H Shares	9.88%
Shanghai Qinghe Enterprise Management Consultation Center (Limited Partnership) ⁽³⁾	20,279,653 H Shares	2.12%	20,279,653 H Shares	2.09%
Shanghai Qingzhen Enterprise Management Consultation Center (Limited Partnership) ⁽¹⁾	16,963,831 H Shares	1.77%	16,963,831 H Shares	1.75%
Public shareholders				
The placees	—	—	12,900,000 H Shares	1.33%
Other holders of the H Shares	334,970,376 H Shares	34.94%	334,970,376 H Shares	34.48%
Holders of the Domestic Shares	6,599,543 Domestic Shares	0.69%	6,599,543 Domestic Shares	0.68%
Total:	958,593,831	100%	971,493,831	100%

Notes:

- (1) Dr. He Chao, the executive Director, held approximately 54.05% interest in Shanghai Qingzhen Enterprise Management Consultation Center (Limited Partnership) as its limited partner. By virtue of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong), Shanghai Latent Artificial Intelligence Co., Ltd. and Shanghai Qingzhen Enterprise Management Consultation Center (Limited Partnership) are parties acting in-concert.
- (2) Dr. He Chao is a general partner of Shanghai Qingmin Enterprise Management Consultation Center (Limited Partnership).
- (3) Dr. He Chao held approximately 43.12% interest in Shanghai Qinghe Enterprise Management Consultation Center (Limited Partnership) as its limited partner.
- (4) The aggregate of the percentage figures in the table above may not add up to the relevant sub-total or total percentage figures shown due to rounding of the percentage figures to two decimal places. Percentages may not add up to 100% due to rounding.

By order of the Board
Shanghai MicroPort MedBot (Group) Co., Ltd.
Mr. Sun Hongbin
Chairman

Shanghai, China, 5 July 2024

As at the date of this announcement, the executive Director is Dr. He Chao, the non-executive Directors are Mr. Sun Hongbin, Mr. Chen Xinxing and Mr. Chen Chen, and the independent non-executive Directors are Dr. Li Minghua, Mr. Yao Haisong and Mr. Mui Wing Hong.